These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 26378638)
41. Reply to: Correspondence on "The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease". Xu X; Nan Y J Hepatol; 2022 Feb; 76(2):484-485. PubMed ID: 34774637 [No Abstract] [Full Text] [Related]
42. Pathological features of fatty liver disease. Yeh MM; Brunt EM Gastroenterology; 2014 Oct; 147(4):754-64. PubMed ID: 25109884 [TBL] [Abstract][Full Text] [Related]
43. [Prevalence of nonalcoholic fatty liver disease in young patients with abdominal obesity and hypertension]. Chulkov VS; Sumerkina VA; Abramovskikh OS; Chulkov VS Eksp Klin Gastroenterol; 2014; (11):42-5. PubMed ID: 25842663 [TBL] [Abstract][Full Text] [Related]
44. A REVIEW OF INTERNATIONAL AND NATIONAL CLINICAL GUIDELINES FOR THE DIAGNOSIS AND TREATMENT-OF NONALCOHOLIC FATTY LIVER DISEASE. Golovanova EV; Lazebnik LB Eksp Klin Gastroenterol; 2016; (11):76-83. PubMed ID: 29889450 [TBL] [Abstract][Full Text] [Related]
45. Evidence-Based Medicine and the Problem of Healthy Volunteers. Marchesini G; Marchignoli F; Petta S Ann Hepatol; 2017 November-December,; 16(6):832-834. PubMed ID: 29055914 [TBL] [Abstract][Full Text] [Related]
46. Relationship between psoriasis and non-alcoholic fatty liver disease - Updated systematic review and adjusted meta-analysis. Phan K; Onggo J; Charlton O; Smith SD Australas J Dermatol; 2019 Nov; 60(4):e352-e355. PubMed ID: 30906989 [No Abstract] [Full Text] [Related]
47. [Introduction to the APASL clinical guidelines on the management of metabolic-associated fatty liver disease]. Shi YW; Xiao QQ; Fan JG Zhonghua Gan Zang Bing Za Zhi; 2020 Nov; 28(11):915-917. PubMed ID: 33256275 [TBL] [Abstract][Full Text] [Related]
48. Liver involvement in pediatric celiac disease. Anania C; De Luca E; De Castro G; Chiesa C; Pacifico L World J Gastroenterol; 2015 May; 21(19):5813-22. PubMed ID: 26019445 [TBL] [Abstract][Full Text] [Related]
49. Systemic Complications of Nonalcoholic Fatty Liver Disease: When the Liver Is Not an Innocent Bystander. Vanni E; Marengo A; Mezzabotta L; Bugianesi E Semin Liver Dis; 2015 Aug; 35(3):236-49. PubMed ID: 26378641 [TBL] [Abstract][Full Text] [Related]
50. [[Current approaches to diagnosing and treating nonalcoholic fatty liver disease]. Drapkina OM; Deeva TA; Volkova NP; Ivashkin VT Ter Arkh; 2014; 86(10):116-23. PubMed ID: 25509904 [TBL] [Abstract][Full Text] [Related]
51. [Interview with PD Dr. Anton Gillessen, Münster. Non-alcoholic fatty liver: change in the life style!]. Gillessen A MMW Fortschr Med; 2015 Jan; 157(1):69. PubMed ID: 25767868 [No Abstract] [Full Text] [Related]
52. Nonalcoholic fatty liver disease is an independent risk factor for atherosclerosis in young adult men. Ozturk K; Uygun A; Guler AK; Demirci H; Ozdemir C; Cakir M; Sakin YS; Turker T; Sari S; Demirbas S; Karslıoğlu Y; Saglam M Atherosclerosis; 2015 Jun; 240(2):380-6. PubMed ID: 25875390 [TBL] [Abstract][Full Text] [Related]
53. Prevalence, risk factors, and predictors of nonalcoholic fatty liver disease among schoolchildren: a hospital-based study in Alexandria, Egypt. Alkassabany YM; Farghaly AG; El-Ghitany EM Arab J Gastroenterol; 2014 Jun; 15(2):76-81. PubMed ID: 25097051 [TBL] [Abstract][Full Text] [Related]
54. Nonalcoholic Fatty Liver Disease: Epidemiology, Natural History, and Diagnostic Challenges. Cholankeril G; Perumpail RB; Pham EA; Ahmed A; Harrison SA Hepatology; 2016 Sep; 64(3):954. PubMed ID: 27388553 [No Abstract] [Full Text] [Related]